An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension

Trial Profile

An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Droxidopa (Primary)
  • Indications Orthostatic hypotension
  • Focus Therapeutic Use
  • Sponsors Chelsea Therapeutics
  • Most Recent Events

    • 06 Jan 2017 Results (n=907) assessing CV safety of Droxidopa using patient data from NOH-301, NOH-302, NOH-303, NOH-304 and NOH-306 trials, published in the American Journal of Cardiology.
    • 21 Apr 2016 Results of an integrated analysis from five trials assessing cardiovascular safety presented at the 68th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2016 Results from NOH306 and NOH303 trials presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top